Biogen: Kursziel nach Zahlen gesenkt - Aktienanalyse
New York (www.aktiencheck.de) - Biogen-Aktienanalyse von J.P. Morgan Securities:
Chris Schott, Analyst von J.P. Morgan Securities, senkt in einer aktuellen Aktienanalyse…
140,425€
-1,56%
Echtzeit-Aktienkurs Biogen Inc.
Bid:
Ask:
Nachrichten zur Biogen Inc. Aktie
Biogen: Gemischte Q3-Ergebnisse - Aktienanalyse
London (www.aktiencheck.de) - Biogen-Aktienanalyse von Barclays:
Carter Gould, Analyst von Barclays, senkt in einer aktuellen Aktienanalyse das Kursziel für die Aktie…
Biogens Uncertain Strategic Pivots Amidst MS Market Challenges
…
Biogen (BIIB) Q3 2023 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2023.…
Biogen lowers full-year earnings guidance, 3Q revenue beats expectations
Biogen Inc (NASDAQ:BIIB) revised its full-year earnings guidance downward due to acquisition-related costs following the company’s $7.3 billion bid for...…
Biogen swings to Q3 growth after Reata acquisition (update)
…
Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript
…
Leichter Wertverlust bei der Biogen-Aktie (215,1004 €)
Im Minus liegt derzeit die Biogen-Aktie . Der jüngste Kurs betrug 229,90 US-Dollar. Ein Preisabschlag in Höhe von 15,72 US-Dollar…
Biogen Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Biogen cuts annual profit forecast as higher costs persist By Reuters
Biogen cuts annual profit forecast as higher costs persist…
Biogen stock pops after earnings beat By Investing.com
Biogen stock pops after earnings beat…
: Biogen quarterly results top estimates despite complex launch of new Alzheimer’s treatment
Company focuses on new products in Alzheimers, postpartum depression as multiple sclerosis product revenues decline…
Biogen cuts annual profit forecast on persistent higher costs
…
Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View
Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact…
LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period
Stockholm, Sweden, November 7, 2023 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report…
Biogen Appoints Monish Patolawala to its Board of Directors
Biogen Appoints Monish Patolawala to its Board of Directors…
Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?
Biogens (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis…
Earnings playbook: How to trade the biggest reports this week, including Disney
More than 45 S&P 500 names are slated to report this week, including Disney, Biogen and D.R. Horton.…
Eilt: Globaler Lizenzdeal voraus - Neuer 407% Biotech Aktientip nach 31.205% mit Amgen und 134.452% mit Biogen ($BIIB)
Calgary (www.aktiencheck.de, Anzeige)
Einschätzung
Strong OutperformerKurszieleKursziel 12M: 1,00 EUR
Kurschance: 238%
Kursziel 24M: 1,50 EUR
Kurschance: 407%StammdatenISIN: CA98420Q2071
WKN: A3C9TS
Ticker: ANU
TSXV: XRTX.V
NASDAQ: XRTXKursdatenKurs: 0,296 EUR
52W Hoch:…
Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy
…
SCLX: An Innovative and Growing Pain Management Company
By Brad Sorensen, CFA
NASDAQ:SCLX
READ THE FULL SCLX RESEARCH REPORT
Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on…
More convenient form of breakthrough Alzheimers drug Leqembi shows promising results in study
Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the…
Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake
Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake…
: Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake
Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.…
Biogen updates Phase 1 data for Ionis-partnered Alzheimer’s drug
…
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data…
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its…
Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…
FDA approves Biogen’s biosimilar to Roches arthritis drug Actemra
…
: Biogen gets FDA approval for biotech treatment similar to Roche’s Actemra
Biogen Inc. BIIB said late Friday the Food and Drug Administration approved its biosimilar version of Roche CH:ROG‘s arthritis treatment…
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug…
Sangamo Therapeutics 10% owner Biogen discloses sale of 6M shares
…
Oligonucleotide API Market revenue to surpass USD 5 Billion by 2035, says Research Nester
Major Oligonucleotide API Market players include Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen Inc., Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden…
Biogen Completes Acquisition of Reata Pharmaceuticals
CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of…
Reata shareholders clear buyout deal with Biogen
…
IBD (Ulcerative Colitis and Crohns Disease) Treatment Market revenue to hit USD 36 Billion by 2033, says Research Nester
Leading IBD (Ulcerative Colitis and Crohns Disease) Treatment Market players include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Bristol…
Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment
Biogen Inc. BIIB shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis…
Biotech Report: Evotec (EVT) klettern, MorphoSys (MOR) und Qiagen (QIA) behauptet
Biotech-Aktien zeigen sich im deutschen Handel erneut fester. Unter anderem können Evotec und Qiagen zulegen. An der Wall Street…
Beschäftigte des US-Biotechnologiekonzerns Biogen in Baar zittern um ihren Arbeitsplatz
Der Medikamentenhersteller Biogen streicht weltweit mehr als jede neunte Stelle. Da vorab Funktionen innerhalb der Zentrale verschwinden sollen, geht am…
Biogen sticht Sanofi aus – um 50 Cent
Große Pharma- und Biotech-Unternehmen befinden sich auf der Suche nach interessanten Übernahmezielen. Vor Kurzem ist Biogen fündig geworden und hat…
Biogen/ Sage expected to hike price for new depression drug after narrow label
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues
Denalis (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen....…
XETR : US09062X1037: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
XFRA : IDP: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
XFRA : ZERTIFIKATEBOERSE RESUMPTION OF UNDERL.: US09062X1037
ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US09062X1037 SIND AB 13:41 CET WIEDER IN DEN HANDEL AUFGENOMMEN.
ALL STRUCTURED PRODUCTS WITH UNDERLYING US09062X1037…
Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug
The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for…
Biogen, Sage face uphill battle with postpartum depression pill
...By Bhanvi Satija and Mariam Sunny
(Reuters) - The U.S. drug......…
XETR : US09062X1037: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …
XFRA : ZERTIFIKATEBOERSE SUSPENSION OF UNDERL.: US09062X1037
ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US09062X1037 SIND AB SOFORT VOM HANDEL AUSGESETZT BIS AUF WEITERES.
ALL STRUCTURED PRODUCTS WITH UNDERLYING US09062X1037…
XFRA : IDP: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …